Reese’s Peanut Butter Cup Recipe Debate: Hershey Responds as Cocoa Prices Shift 
Anderson Cooper to Exit CBS News’ 60 Minutes After Nearly 20 Years 
Hedge Funds Cut Nvidia, Amazon and Microsoft Stakes as AI Valuation Concerns Rise 
Mitsui Kinzoku Stock Surges to Record High After Profit Forecast Upgrade and Dividend Increase 
Vietnam Airlines, Vietjet, and Sun PhuQuoc Airways Sign Major Boeing Aircraft Deals Amid U.S.–Vietnam Trade Talks 
YouTube Outage Disrupts Thousands Worldwide as Recommendation System Fails 
Qualcomm to Invest $150 Million in India AI Startups, Strengthening Presence in Growing Market 
Federal Court Fines Mobil Oil Australia A$16 Million for Misleading Fuel Claims 
Starboard Value Targets Tripadvisor Board Overhaul Amid Stock Slump 
Thomas Pritzker to Step Down as Hyatt Executive Chairman After Epstein Ties Acknowledged 
BlueScope Steel Forecasts Stronger Second-Half Earnings, Shares Rise Above Rejected Buyout Offer 
Disney Issues Cease-and-Desist to ByteDance Over Alleged AI Copyright Infringement 
Treasury Wine Estates Profit Falls 46% as China and U.S. Inventory Reset Weighs on Earnings 
AstroTurf Expands Footprint at Colorado as Buffaloes Complete Second Installation in 12 Months 
Freedom Finance and Binance Join Forces in Digital Assets 
Medical Groups Sue FTC Over Gender-Affirming Care Investigations Amid Trump Policy Dispute 
Ireland’s Data Protection Commission Launches GDPR Investigation Into X’s AI Chatbot Grok 
Press release - No 11 / 2018
Zealand Pharma to attend Deutsche Bank Securities 43rd Annual Health Care Conference, in Boston on May 8, 2018
Copenhagen, 2 May, 2018 - Mats Blom, Executive Vice President and Chief Financial Officer (CFO) of Zealand Pharma, will be presenting at the Deutsche Bank Securities 43rd Annual Health Care Conference, in Boston on May 8, 2018.
For further information, please contact:
Mats Blom, Executive Vice President and Chief Financial Officer
Tel.: +45 31 53 79 73, e-mail: [email protected]
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand has a late stage clinical portfolio of proprietary product candidates focusing on specialty gastrointestinal and metabolic diseases. In addition, it has two marketed products, commercialized by Sanofi, and two product candidates under license collaboration with Boehringer Ingelheim.
Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the Company's business and activities, please visit www.zealandpharma.com or follow Zealand on LinkedIn or Twitter @ZealandPharma.
Attachment
